Journal of Research in Pharmacy Practice

ORIGINAL ARTICLE
Year
: 2018  |  Volume : 7  |  Issue : 4  |  Page : 178--181

Serum cystatin C for evaluation of acute kidney injury in adults treated with colistin


Rozina Abbasi Larki1, Bahareh Jamali1, Mohsen Meidani2, Sarah Mousavi3 
1 Department of Internal Medicine, Yasuj University of Medical Sciences, Yasuj, Iran
2 Department of Infectious Diseases, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence Address:
Dr. Sarah Mousavi
Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan
Iran

Objective: Recent studies have shown that serum cystatin C (Cys C) is a better marker for measuring the glomerular filtration rate and may rise more quickly with acute kidney injury (AKI). The purpose of this study was to evaluate the clinical application of serum Cys C to predict colistin-induced nephrotoxicity in comparison with serum creatinine (SCr). Methods: Thirty-two adult patients with no history of acute or chronic kidney injury having been planned to receive intravenous colistin for an anticipated duration of at least 1 week for any indication were recruited. At baseline and 5 days after colistin treatment, serum Cys C as well as creatinine levels were measured. The incidence of colistin-induced acute renal failure was defined according to the AKIN criteria for SCr. Rise in concentration of Cys C by more than 10% from baseline considered as AKI. Findings: Colistin-induced nephrotoxicity (defined as SCr ≥0.3 mg/dl) occurred in 6 patients (18.8%). A Cys C increase concentration ≥10% after 5 days of colistin treatment was detected in 15 patients (46.9%). There was a poor agreement between the presence and absence of any SCr-AKI and Cys C-AKI (κ = 0.28, P = 0.04). Conclusion: Serum Cys C is a better marker of renal function in early stages of AKI and predictive of persistent AKI on colistin treatment.


How to cite this article:
Larki RA, Jamali B, Meidani M, Mousavi S. Serum cystatin C for evaluation of acute kidney injury in adults treated with colistin.J Res Pharm Pract 2018;7:178-181


How to cite this URL:
Larki RA, Jamali B, Meidani M, Mousavi S. Serum cystatin C for evaluation of acute kidney injury in adults treated with colistin. J Res Pharm Pract [serial online] 2018 [cited 2019 Mar 19 ];7:178-181
Available from: http://www.jrpp.net/article.asp?issn=2319-9644;year=2018;volume=7;issue=4;spage=178;epage=181;aulast=Larki;type=0